In vitro aceclofenac release from IPN matrix tablets composed of chitosan-tamarind seed polysaccharide.

This communication describes the formulation and in vitro evaluation of IPN matrix tablets of aceclofenac. IPN microparticles using chitosan and tamarind seed polysaccharide blend was prepared using glutaraldehyde as cross-linker. The drug entrapment efficiency and average particle size of these microparticles was found to be 91.97±1.30% and 498.12±38.67 µm, respectively. These IPN microparticles were characterized by scanning electron microscopy (SEM) and powder X-ray diffraction (P-XRD) study. These microparticles were compressed with tablet excipients through direct compression technique. These matrix tablets showed sustained aceclofenac release over 8 h. These matrix tablets might be helpful to minimize dosing frequency and reduction of various side effects during prolong period of treatment.

Carbopol gel containing chitosan-egg albumin nanoparticles for transdermal aceclofenac delivery.

In the present work, various aceclofenac-loaded chitosan-egg albumin nanoparticles were prepared through heat coagulation method. These aceclofenac-loaded nanoparticles were characterized by FE-SEM, FTIR, DSC and P-XRD analyses. The in vitro drug release from nanoparticles showed sustained drug release over 8h. Aceclofenac-loaded nanoparticles (prepared using 200mg chitosan, 500 mg egg albumin and 2% (w/v) NaTPP) showed highest drug entrapment (96.32±1.52%), 352.90 nm average particle diameter and -22.10 mV zeta potential, which was used for further preparation of Carbopol 940 gel for transdermal application. The prepared gel exhibited sustained ex vivo permeation of aceclofenac over 8h through excised mouse skin. The in vivo anti-inflammatory activity in carrageenean-induced rats demonstrated comparative higher inhibition of swelling of rat paw edema by the prepared gel compared with that of the marketed aceclofenac gel over 4 h.

Development of chitosan-based nanoparticles through inter-polymeric complexation for oral drug delivery.

The possibility of inter-polymeric complexation of cationic chitosan and anionic egg albumin stabilized with PEG 400 to develop novel nanoparticles for oral delivery of alprazolam by heat coagulation method at pH 5.4 and 80 °C. Nine formulations were prepared by changing the concentration of chitosan, PEG 400 and heating time. The alprazolam entrapment efficiency of these nanoparticles was in the range of 68.12±1.27 to 99.37±4.86%. These nanoparticles were characterized by FTIR, DSC, P-XRD and FE-SEM analysis. Average particle diameter, poly-dispersity index and zeta potential of these nanoparticles were found 259.60 nm, 0.501, and -9.00 mV, respectively. The in vitro drug release from these alprazolam-loaded nanoparticles showed sustained drug release over a period of 24h. In conclusion, these newly developed chitosan-egg albumin-PEG nanoparticles were found to be a promising vehicle for sustained release delivery of lipophilic drugs.

Aceclofenac-loaded unsaturated esterified alginate/gellan gum microspheres: in vitro and in vivo assessment.

Aceclofenac-loaded alginate/gellan gum microspheres for prolonged aceclofenac release were prepared through maleic anhydride-induced unsaturated esterification. The drug entrapment efficiency of these microspheres was found 39.30 ± 1.28% to 98.46 ± 0.40% and their average particle sizes were 270-490 µm. These microspheres were characterized by FTIR, DSC, P-XRD and SEM analysis. The in vitro dissolution indicated prolonged sustained release of aceclofenac over 6h, which also followed the Korsmeyer-Peppas model (R(2)=0.9571-0.9952). The microspheres prepared through 3% (w/v) maleic anhydride-induced esterification exhibited comparatively slower drug-release. Most of the microspheres were followed Fickian diffusion mechanism except the microspheres containing higher gellan gum content, which followed anomalous (non-Fickian) diffusion. The in vivo results showed sustained systemic absorption of aceclofenac in rabbits and excellent anti-inflammatory activity in carrageenan-induced rats after oral administration over prolonged period.

Aceclofenac-loaded chitosan-tamarind seed polysaccharide interpenetrating polymeric network microparticles.

The present work deals with the preparation, characterization and evaluation of glutaraldehyde cross-linked chitosan-tamarind seed polysaccharide (TSP) interpenetrating polymeric network (IPN) microparticles for prolonged aceclofenac release. The drug entrapment efficiency of these microparticles was found 85.84±1.75 to 91.97±1.30% and their average particle sizes were ranged from 490.55±23.24 to 621.60±53.57 µm. These chitosan-TSP IPN microparticles were characterized by FTIR, DSC, and SEM analyses. The in vitro drug release from these aceclofenac-loaded chitosan-TSP IPN microparticles showed sustained release of aceclofenac over 8h and followed the Korsmeyer-Peppas model (R(2)=0.9809-0.9828) with anomalous (non-Fickian) diffusion drug release mechanism. The in vivo studies exhibited sustained anti-inflammatory activity in carrageenan-induced rats over prolonged period after oral administration of these newly developed aceclofenac-loaded IPN microparticles.

Evaluation of ionotropic cross-linked chitosan/gelatin B microspheres of tramadol hydrochloride.

Microspheres of tramadol hydrochloride (TM) for oral delivery were prepared by complex coacervation method without the use of chemical cross-linking agents such as glutaraldehyde to avoid the toxic reactions and other undesirable effects of the chemical cross-linking agents. Alternatively, ionotropic gelation was employed by using sodium-tripolyphosphate as cross-linking agent. Chitosan and gelatin B were used as polymer and copolymer, respectively. All the prepared microspheres were subjected to various physicochemical studies, such as drug-polymer compatibility by thin layer chromatography (TLC) and Fourier transform infrared (FTIR) spectroscopy, surface morphology by scanning electron microscopy, frequency distribution, drug entrapment efficiency, in vitro drug release characteristics and release kinetics. The physical state of drug in the microspheres was determined by differential scanning calorimetry (DSC) and X-ray diffractometry (XRD). TLC and FTIR studies indicated no drug-polymer incompatibility. All the microspheres showed initial burst release followed by a fickian diffusion mechanism. DSC and XRD analysis indicated that the TM trapped in the microspheres existed in an amorphous or disordered-crystalline status in the polymer matrix. From the preliminary trials, it was observed that it may be possible to formulate TM microspheres by using biodegradable natural polymers such as chitosan and gelatin B to overcome the drawbacks of TM and to increase the patient compliance.

Evaluation of ketorolac tromethamine microspheres by chitosan/gelatin B complex coacervation.

Microspheres (MS) of Ketorolac Tromethamine (KT) for oral delivery were prepared by complex coacervation (method-1) and simple coacervation (method-2) methods without the use of chemical crossâlinking agent (glutaraldehyde) to avoid the toxic reactions and other undesirable effects of the chemical cross-linking agents. Alternatively, ionotropic gelation was employed by using sodium-tripolyphosphate (Na-TPP) as cross linking agent. Chitosan and gelatin B were used as polymer and copolymer respectively. All the prepared microspheres were subjected to various physico-chemical studies, such as drug-polymer compatibility by Thin Layer Chromatography (TLC) and Fourier Transform Infra Red Spectroscopy (FTIR), surface morphology by Scanning Electron Microscopy (SEM), frequency distribution, encapsulation efficiency, in-vitro drug release characteristics and release kinetics. The physical state of drug in the microspheres was determined by Differential Scanning Calorimetry (DSC) and X-ray powder Diffractometry (XRD). TLC and FTIR studies indicated no drug-polymer incompatibility. All the MS showed release of drug by a fickian diffusion mechanism. DSC and XRD analysis indicated that the KT trapped in the microspheres existed in an amorphous or disordered-crystalline status in the polymer matrix. It is possible to design a controlled drug delivery system for the prolonged release of KT, improving therapy by possible reduction of time intervals between administrations.

Development and evaluation of calcium alginate beads prepared by sequential and simultaneous methods

The objective of this study was to develop a sustained release dosage form of Trimetazidine dihydrochloride (TMZ) using a natural polymeric carrier prepared in a completely aqueous environment. TMZ was entrapped in calcium alginate beads prepared with sodium alginate by the ionotropic gelation method using calcium chloride as a crosslinking agent. The drug was incorporated either into preformed calcium alginate gel beads (sequential method) or incorporated simultaneously during the gelation stage (simultaneous method). The beads were evaluated for particle size and surface morphology using optical microscopy and SEM, respectively. Beads produced by the sequential method had higher drug entrapment. Drug entrapment in the sequential method was higher with increased CaCl2 and polymer concentration but lower with increased drug concentration. In the simultaneous method, drug entrapment was higher when polymer and drug concentration were increased and also rose to a certain extent with increase in CaCl2 concentration, where further increase resulted in lower drug loading. FTIR studies revealed that there is no interaction between drug and CaCl2. XRD studies showed that the crystalline drug changed to an amorphous state after formulation. Release characteristics of the TMZ loaded calcium alginate beads were studied in enzyme-free simulated gastric and intestinal fluid.

O objetivo deste estudo foi desenvolver forma de liberação controlada de dicloridrato de trimetazidina (TMZ) utilizando transportador plomérico natural em ambiente completamente aquoso. A TMZ foi presa em pérolas de alginato de cálcio preparadas com alginato de sódio pelo método de gelatinização ionotrópica, usando cloreto de cálcio como agente de formação de ligações cruzadas. O fármaco foi incorporado nas pérolas de gel de alginato de cálcio (método sequencial) ou incorporado, simultaneamente, durante o estágio de gelificação (método simultâneo). As pérolas foram avaliadas quanto ao tamanho das partículas e morfologia da superfície utilizando microscopia óptica de SEM, respectivamente. As pérolas produzidas pelo método sequencial apresentaram maior capacidade de inclusão. No método sequencial, a inclusão de fármaco foi maior com o aumento de CaCl2 e da concentração do plímero, mas menor com o aumento da concentração de fármaco. No método simultâneo, a inclusão de fármaco foi mais alta quando as concentrações de fármaco e plímero foram aumentadas e, também, atingiram certa extensão com aumento na concentração de CaCl2, cujo aumento posterior resultou em carga menor de fármaco. Estudos de FTIR revelaram que não há interação entre fármaco e CaCl2. Estudos de XRD mostraram que o fármaco mudou do estado cristalino para o amorfo após a formulação. As características de liberação de TMZ das pérolas carregadas com alginato de cálcio foram estudadas em fluidos simulados, gástrico e intestinal, livres de enzima.

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.

Similar to the low molecular weight traditional drugs, biopharmaceuticals are capable of producing not only therapeutic effects but also side effects provided if the dose of these compounds exceeds certain concentration and/or if the exposure duration of these compounds at subtoxic doses is being lengthened. In addition, a major drawback of biopharmaceuticals is the risk of antibody formation. Following the administration of biopharmaceuticals into human body, the formation of antidrug-antibody (ADA) or neutralizing antibody and other general immune system effects (including allergy, anaphylaxis, or serum sickness) are of clinical concern regarding therapeutic efficacy and patient safety. For example, drug-induced neutralizing antibodies to erythropoietin (EPO) result in pure red cell aplasia, whereas drug-induced acquired anti-factor VIII antibodies worsen the pathology associated with hemophilia. Since most of the already developed or under development biopharmaceuticals are to some extent immunogenic, the regulatory agencies insist to conduct potential ADA formation during the drug development process itself. This review encompasses a short overview on the clinical concerns of immunogenicity produced at cellular levels by growth hormone, interferon-alpha, EPO, factor VIII, and factor IX following their parenteral administration into human body. Clinical concerns related to immunogenicity produced by the biosimilar versions of these drugs are also presented wherever possible.

Sustained release of a water-soluble drug from alginate matrix tablets prepared by wet granulation method.

Alginate matrix tablet of diltiazem hydrochloride (DTZ), a water-soluble drug, was prepared using sodium alginate (SAL) and calcium gluconate (CG) by the conventional wet granulation method for sustained release of the drug. The effect of formulation variables like SAL/CG ratio, drug load, microenvironmental pH modulator, and processing variable like compression force on the extent of drug release was examined. The tablets prepared with 1:2 w/w ratio of SAL/CG produced the most sustained release of the drug extending up to 13.5 h. Above and below this ratio, the drug release was faster. The drug load and the hardness of the tablets produced minimal variation in drug release. The addition of alkaline or acidic microenvironmental modulators did not extend the release; instead, these excipients produced somewhat faster release of diltiazem. This study revealed that proper selection of SAL/CG ratio is important to produce alginate matrix tablet by wet granulation method for sustained release of DTZ.

Studies in the development of nateglinide loaded calcium alginate and chitosan coated calcium alginate beads.

Nateglinide loaded alginate-chitosan beads were prepared by ionic gelation method for controlling the drug release by using various combinations of chitosan and Ca2+ as cation and alginate as anion. IR spectrometry, scanning electron microscopy, differential scanning calorimetry and X-ray powder diffractometry were used to investigate the physicochemical characteristics of the drug in the bead formulations. The calcium content in beads was determined by atomic absorption spectroscopy. The swelling ability of the beads in different media (pH 1.2, 4.5, 6.8) has been found to be dependent on the presence of polyelectrolyte complex of the beads and the pH of the media. The ability to release the Nateglinide was examined as a function of chitosan and calcium chloride content in the gelation medium. It is evident that the rate of drug release and its kinetics could be controlled by changing the chitosan and the calcium chloride concentrations. Calcium alginate beads released more than 95% of drug with in 8 h; whereas coated beads sustained the drug release and released only 75-80% of drug. The drug release mechanism analyzed indicates that the release follows either "anomalous transport" or "case-II transport".

Crystal modification of dipyridamole using different solvents and crystallization conditions.

Dipyridamole crystals having different types of habits, improved dissolution rate were prepared by recrystallization from selected solvents, such as acetonitrile, benzene and methanol (Method I); crystals have also been made by solvent change using methanolic solution of dipyridamole in the presence of 2% solutions of Tween-80, Povidone K30 and polyethylene glycol (PEG) 4000 (Method II). Scanning electron microscopy, X-ray powder diffractometry, IR spectrometry and differential scanning calorimetry were used to investigate the physicochemical characteristics of the crystals. The comparative dissolution behavior of the newly developed crystals and that of the untreated dipyridamole were also studied. It was found that the newly developed crystals were different from each other with respect to physical properties but are chemically identical. The crystals, obtained (Method I) from benzene and acetonitrile, produced needle shaped crystals and that obtained from methanol produced rectangular shaped crystals. But the crystals obtained (Method II) with the methanolic solution of the drug in the presence of Tween-80, Povidone K30 and PEG-4000 produced smooth needle shaped crystals. X-ray diffraction spectra and differential scanning calorimetry study of the newly developed crystals, clearly indicate that dipyridamole exist in different crystal modification. The dissolution rate of newly developed crystals was found to be greater than the pure drug dipyridamole. Stability studies at 40 degrees C (75% RH) for 1 month for the modified crystals as well as the pure drug did show some changes in the XRD and DSC but not in IR studies.